Evidence to support the effectiveness of this medication for treating weight loss is very limited and of poor quality. Use may lead to increased risk of adverse events, including dyspnea, edema, thromboembolic phenomena, and death.
- FDA monograph: Megace
- Ruiz Garcia V, Lopez-Briz E, Carbonell Sanchis R, et al. (2013). Megesterol acetate for treatment of anorexia-cachexia syndrome (review).
- Cochrane Database of Systematic Reviews. 3:CD004310.